US Pharma MarketingNovartis taps Antares in small molecule discovery pact with $105M upfront
Antares Therapeutics inks $105M upfront deal with Novartis to discover small molecules against undruggable cancer targets, with up to $1.8B in milestones. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push…
Antares Therapeutics will be collaborating with Novartis to find unique small molecule candidates for multiple “undruggable” cancer targets, with the biotech receiving $105 million upfront.
“We're discovering and developing with Novartis targets that have never ...
Source: Endpoints News